Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3054480 | European Journal of Paediatric Neurology | 2009 | 4 Pages |
Abstract
Levetiracetam (LEV) is approved as second line treatment for partial onset seizures in adults and children older than four years of age. Recently, an intravenous formulation was developed as an alternative to standard oral medication. We report the successful treatment of two children suffering from myoclonic status epilepticus with intravenous LEV. Intravenous application of LEV was safe and not associated with significant side effects. In conclusion, intravenous application of LEV appears to be a further option in treatment of children with myoclonic status epilepticus.
Related Topics
Life Sciences
Neuroscience
Developmental Neuroscience
Authors
E. Haberlandt, S. Baumgartner Sigl, S. Scholl-Buergi, D. Karall, M. Rauchenzauner, K. Rostásy,